JP2025511847A5 - - Google Patents
Info
- Publication number
- JP2025511847A5 JP2025511847A5 JP2024559386A JP2024559386A JP2025511847A5 JP 2025511847 A5 JP2025511847 A5 JP 2025511847A5 JP 2024559386 A JP2024559386 A JP 2024559386A JP 2024559386 A JP2024559386 A JP 2024559386A JP 2025511847 A5 JP2025511847 A5 JP 2025511847A5
- Authority
- JP
- Japan
- Prior art keywords
- diffraction pattern
- ray
- crystal morphology
- measured
- ranifibranol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305456.0 | 2022-04-05 | ||
| EP22305456 | 2022-04-05 | ||
| PCT/EP2023/058743 WO2023194339A1 (en) | 2022-04-05 | 2023-04-04 | Crystalline form of lanifibranor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511847A JP2025511847A (ja) | 2025-04-16 |
| JP2025511847A5 true JP2025511847A5 (enExample) | 2026-04-08 |
Family
ID=81326293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559386A Pending JP2025511847A (ja) | 2022-04-05 | 2023-04-04 | ラニフィブラノールの結晶形態 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250243192A1 (enExample) |
| EP (1) | EP4504725A1 (enExample) |
| JP (1) | JP2025511847A (enExample) |
| KR (1) | KR20250002337A (enExample) |
| CN (1) | CN119301120A (enExample) |
| AR (1) | AR128985A1 (enExample) |
| AU (1) | AU2023250118A1 (enExample) |
| CA (1) | CA3247273A1 (enExample) |
| IL (1) | IL316075A (enExample) |
| MX (1) | MX2024012348A (enExample) |
| PY (1) | PY2324870A (enExample) |
| TW (1) | TW202404966A (enExample) |
| UY (1) | UY40216A (enExample) |
| WO (1) | WO2023194339A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240343723A1 (en) * | 2021-08-12 | 2024-10-17 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of lanifibranor, preparation method therefor, and use thereof |
| AU2024208998A1 (en) | 2023-01-19 | 2025-08-21 | Inventiva | Lanifibranor formulation |
| IL325022A (en) | 2023-06-05 | 2026-01-01 | Inventiva | Nifibranor for use in the treatment of splenic vasodilation in a patient with liver disease |
| AR133887A1 (es) * | 2023-09-22 | 2025-11-12 | Inventiva | Método de fabricación de lanifibranor |
| WO2025132989A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025132955A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025191292A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Methods and monitoring of treatment with lanifibranor |
| TW202543596A (zh) | 2024-03-15 | 2025-11-16 | 法商因文帝華公司 | 預防接受過氧化物酶體增生劑活化受體（ppar）促效劑治療患者之血液病症 |
| WO2025238200A1 (en) | 2024-05-17 | 2025-11-20 | Inventiva | Treatment of a liver disease in patients with hepatic impairment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
| WO2022143479A1 (zh) | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| US20240246949A1 (en) | 2021-06-10 | 2024-07-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of lanifibranor and process for preparation thereof |
| CN115466252A (zh) | 2021-06-11 | 2022-12-13 | 上海希迈医药科技有限公司 | 一种Lanifibranor的晶型及其制备方法 |
| US20240343723A1 (en) | 2021-08-12 | 2024-10-17 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of lanifibranor, preparation method therefor, and use thereof |
-
2023
- 2023-03-31 TW TW112112450A patent/TW202404966A/zh unknown
- 2023-04-04 EP EP23717474.3A patent/EP4504725A1/en active Pending
- 2023-04-04 US US18/854,287 patent/US20250243192A1/en active Pending
- 2023-04-04 WO PCT/EP2023/058743 patent/WO2023194339A1/en not_active Ceased
- 2023-04-04 AR ARP230100832A patent/AR128985A1/es unknown
- 2023-04-04 IL IL316075A patent/IL316075A/en unknown
- 2023-04-04 AU AU2023250118A patent/AU2023250118A1/en active Pending
- 2023-04-04 KR KR1020247036771A patent/KR20250002337A/ko active Pending
- 2023-04-04 PY PY202302324870A patent/PY2324870A/es unknown
- 2023-04-04 CA CA3247273A patent/CA3247273A1/en active Pending
- 2023-04-04 JP JP2024559386A patent/JP2025511847A/ja active Pending
- 2023-04-04 CN CN202380042246.2A patent/CN119301120A/zh active Pending
- 2023-04-10 UY UY0001040216A patent/UY40216A/es unknown
-
2024
- 2024-10-04 MX MX2024012348A patent/MX2024012348A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025511847A5 (enExample) | ||
| JP5714824B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| JP2025176008A5 (enExample) | ||
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| TW200813081A (en) | Salts and crystal modifications | |
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| JP2012507496A (ja) | レナリドマイドの結晶形およびその調製方法 | |
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2008539258A5 (enExample) | ||
| JP2024095561A5 (enExample) | ||
| JP2009534373A5 (enExample) | ||
| JP2024521412A5 (enExample) | ||
| JP2025536416A5 (enExample) | ||
| KR102657147B1 (ko) | 빌라스틴의 결정형 및 그의 제조 방법 | |
| CN110862389A (zh) | 一种阿哌沙班晶型的制备方法 | |
| EA020545B1 (ru) | Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина | |
| US6673935B2 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis | |
| CN111592485A (zh) | 盐酸替罗非班及其游离碱的晶型及其制备方法 | |
| JP2022540678A5 (enExample) | ||
| WO2013013595A1 (zh) | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 | |
| WO2008092327A1 (fr) | Cristaux demi-hydratés de voglibose, leur procédé de préparation, et préparation pharmaceutique les contenant | |
| JP2023521631A5 (enExample) | ||
| CN111278828A (zh) | 巴瑞替尼磷酸盐的新晶型及其制备方法 | |
| JP2023523165A5 (enExample) | ||
| CN105017120B (zh) | 依折麦布与烟酰胺药物共晶及其制备方法 |